Lucius Pharmaceuticals
International business
Evidence / PK / PD

Exposure, shown without false precision.

A normalized exposure profile based on source-reported constraints for peak timing, six-hour residual exposure and AUC relationship.

Conceptual neurovascular scientific plate related to this page
02 / evidence

The visual is continuous because the methodology is explicit, not because missing concentration data were invented.

pk / pdMCAOpk_pdsource_mapped

Research question

Present source-reported exposure constraints for plasma and brain tissue after dosing.

Methods

ModelMCAO
SpeciesRat
InterventionAildenafil phosphate
Dose5 mg/kg
TimingDose described at 2 h after infarction
ComparatorPlasma versus brain tissue exposure
  • The source summary supports time and relative constraints, not a full absolute concentration series.

Source results

Source result table
EndpointTimepointSource result
Peak time—0.5 h
Residual exposure at 6 h6 hbelow 5% of peak
Brain / plasma AUC ratio—1.24 ×
Dose—5 mg/kg
FIG. 01Mixed · normalized illustrative

Exposure peaks at 0.5 h and falls below 5% of peak by 6 h.

Lieflat Basics F2 hairline-line structure. Solid points show source constraints. Continuous profiles are normalized illustrative reconstructions, not measured intermediate concentrations.
Normalized plasma and brain exposure illustration Peak at 0.5 hours and below 5 percent at 6 hours. Continuous hairlines are normalized illustrations.0 h0.5 h1 h2 h4 h6 h8 hnormalized peak = 100one dot = one illustrative sample0.5 h peak<5% @ 6 h1.24×brain AUC / plasma AUC

Interpretation

The exposure figure is a normalized visual reconstruction of source-reported constraints, not an absolute concentration-time dataset.

Limitations

  • Absolute concentrations and pharmacokinetic parameters such as Cmax, half-life, clearance and volume of distribution are not mapped in v1.
0.5 hPeakSource reported
1.24×Brain AUCvs plasma AUC
5 mg/kgDose contextSource reported
Continue exploring
01Brain exposure in the mapped MCAO context.Study detail for the 5 mg/kg PK/PD context and normalized exposure visualization.02Three models, three questions.A preclinical index covering global cerebral ischemia, MCAO treatment timing and related limitations.03Trace the statement back to its source.The public source register for the current documentation baseline.04IP information with the qualification visible.A structured view of the source-described patent positioning without inferring ownership or legal status.